Bristol-Myers Squibb Co. and Asterand have extended their collaboration providing BMS access to Asterand’s products and services for as long as three years. The agreement will focus on access to Asterand’s PhaseZERO drug discovery services and XpressBANK of human tissue and clinical samples for the continued validation of early drug targets and support for compound optimization. Financial terms were not disclosed. “BMS’s decision is an important validation of Asteran...